DCs transduced with MAGE-1 at an MOI of 100 showed limited toxicity and maximal production of MAGE-1 (data not shown). In this study, CCL3 and CCL20-recruited DCs were modified with a tumor antigen gene and

used as vaccines for an anti-tumor immune response ex vivo and in vivo. Ex vivo, when T cells were primed with MAGE-1-modified DCs and added to tumor cells, they were able to lyse tumor cells efficiently and specifically. High cytolytic activity in association with a Th1-type response could possibly contribute to the profound anti-tumor effects that we observed. In vivo, vaccination with CCL3 and CCL20-recruited DCs modified with MAGE-1 Erlotinib cell line remarkably inhibited subcutaneous tumor growth and size. This observation suggests Venetoclax concentration the treatment potential of these cells as vaccines. In addition, splenic T cells obtained from mice vaccinated with DC-Ad-MAGE-1 produced high levels of IFN-γ and showed specific cytotoxic activity. By contrast, responses induced by nontransduced DCs and TAA-loaded DCs were far less potent. While most DC-based vaccination strategies target solid, non-metastatic tumors, our vaccination strategy employing TAA gene-modified DCs revealed efficacy against metastatic tumors as well. Future work will address the idea that this approach may be a viable one for treatment of gastric cancers in patients. Conclusion In this study,

we demonstrated that F4/80-B220-CD11c+ DC precursors were rapidly recruited into the peripheral blood by administration of CCL3 and for CCL20 in mice. This is essential for preparing DC-based vaccines against tumors. Importantly, vaccination with these DCs modified with MAGE-1, could elicit specific CTL responses to gastric cancer cells, and led to tumor rejection ex vivo and in vivo. These results suggest that an evaluation of this DC-based immunotherapy strategy for gastric cancer patients is an important next step. Acknowledgements This work was supported by the Scientific Research Foundation of Ministry of Public Health of China (No. WKJ20042011). References 1. Hohenberger P, Gretschel S: Gastric cancer. Lancet 2003, 362:305–15.PubMedCrossRef 2. Guida F, Formisano G,

Esposito D, Antonino A, Conte P, Bencivenga M, Persico M, Avallone U: Gastric cancer: surgical treatment and prognostic score. Minerva Chir 2008, 63:93–9.PubMed 3. Liakakos T, Fatourou E: Stage-specific guided adjuvant treatment for gastric cancer. Ann Surg Oncol 2008, 15:2622–3.PubMedCrossRef 4. Gilboa E: DC-based cancer vaccines. J Clin Invest 2007, 117:1195–203.PubMedCrossRef 5. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998, 392:245–52.PubMedCrossRef 6. Zhang Y, Yoneyama H, Wang Y, Ishikawa S, Hashimoto S, Gao JL, Murphy P, Matsushima K: Mobilization of dendritic cell precursors into the circulation by administration of MIP-1α in mice. J Natl Cancer Inst 2004, 96:201–9.PubMedCrossRef 7.